Management of Mycobacterium ulcerans infection in a pregnant woman in Benin using rifampicin and clarithromycin

Ange D Dossou, Ghislain E Sopoh, Christian R Johnson, Yves T Barogui, Dissou Affolabi, Sévérin Y Anagonou, Théophile Zohoun, Françoise Portaels and Kingsley Asiedu
Med J Aust 2008; 189 (9): . || doi: 10.5694/j.1326-5377.2008.tb02166.x
Published online: 3 November 2008

To the Editor: Buruli ulcer, caused by the bacterium Mycobacterium ulcerans, leads to the destruction of skin and sometimes bone. It has been reported in many tropical countries in Africa and in some temperate regions of Australia, Japan and China.1 In 2004, the World Health Organization recommended treatment with the combination of oral rifampicin and intramuscular streptomycin (or amikacin) for 8 weeks.2,3 In-vitro studies and new data from mouse models suggest that combinations of rifampicin with clarithromycin, rifampicin with moxifloxacin, or clarithromycin with moxifloxacin may be as effective as rifampicin and streptomycin.4,5

  • Ange D Dossou1
  • Ghislain E Sopoh1
  • Christian R Johnson2
  • Yves T Barogui3
  • Dissou Affolabi4
  • Sévérin Y Anagonou4
  • Théophile Zohoun5
  • Françoise Portaels6
  • Kingsley Asiedu7

  • 1 Centre de Dépistage et de Traitemente de l’Ulcère, Allada, Benin.
  • 2 Programme National de Lutte contre la Lépre et l’Ulcère de Buruli, Cotonou, Benin.
  • 3 Centre de Dépistage et de Traitemente de l’Ulcère, Lalo, Benin.
  • 4 Laboratoire de Référence des Mycobactéries, Cotonou, Benin.
  • 5 Faculté des Sciences de la Santé, Cotonou, Benin.
  • 6 Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium.
  • 7 Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.



Fondation Luxembourgeoise Raoul Follereau, Luxembourg; Projet Burulico European Union (project reference number, INCO-CT-2005-051476); and the World Health Organization, Geneva.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.